AKR1B8 Inhibitors

Chemical inhibitors of AKR1B8 operate through various modes of action to impede the enzyme's catalytic function. Tolrestat, for instance, achieves inhibition by directly binding to the active site of AKR1B8, thereby obstructing the enzyme's ability to facilitate the reduction of aldehydes and ketones. This direct binding results in a decrease in the production of intracellular sorbitol, which would typically be generated by AKR1B8. Similarly, Sorbinil and Alrestatin competitively bind to the active site of AKR1B8, preventing the enzyme from converting glucose to sorbitol. This competitive inhibition is a common method through which these inhibitors prevent the enzyme from catalyzing its natural reaction within the polyol pathway.

Other inhibitors, such as Epalrestat, form a covalent bond with the active site's catalytic residue, rendering the inhibition irreversible and effectively stopping the enzyme from performing its primary function of glucose reduction. Fidarestat, Zopolrestat, Ranirestat, Minalrestat, Lidorestat, and Imirestat also inhibit AKR1B8 by binding to the aldose reductase active site, each blocking the catalytic mechanism in their unique way, but all ultimately prevent the enzyme from carrying out its reduction reaction. Phenethylbiguanide operates in a similar fashion, through its active site binding. Oxyfedrine, on the other hand, relies on its metabolite, which is an aldose reductase inhibitor, to inhibit AKR1B8. This metabolite interacts with the enzyme's active site, also inhibiting the conversion of glucose to sorbitol. Each inhibitor, despite slight variations in their interaction with AKR1B8, shares the common goal of disrupting the polyol pathway by impeding the enzymatic activity of AKR1B8.